Rett syndrome (RTT) is a severe neurological disorder, affecting mainly females. It is generally caused by mutations in the MECP2 gene. Sleep problems are thought to occur commonly in Rett syndrome, but there has been little research on prevalence or natural history. An Australian population-based registry of cases born since 1976 has been operating since 1993, with current ascertainment at 300. The Australian Rett Syndrome Database (ARSD) consists of information about Rett syndrome cases including their functional ability, behaviour, sleep patterns, medical conditions and genotype. The cases range in age from 2 to 29 years. The aim of this study was to investigate the type and frequency of sleep problems, relationships with age and MECP2 mutation type and to evaluate changes over time. Parents or carers of the subjects with Rett syndrome were asked to complete a questionnaire about sleep problems on three separate occasions (2000, 2002 and 2004). Regression modelling was used to investigate the relationships between sleep problems, age and mutation type. Sleep problems were identified in over 80% of cases. The prevalence of nighttime laughter decreased with age and the prevalence of reported night-time seizures and daytime napping increased with age. The prevalence of sleep problems was highest in cases with a large deletion of the MECP2 gene and in those with the p.R294X or p.R306C mutations. Sleep problems are common in Rett syndrome and there is some variation with age and mutation type.
Background
Rett syndrome is a severe neurodevelopmental disorder, mainly affecting females. The cumulative incidence in Australia is 1.09 per 10,000 females by 12 years of age [1] . Classical Rett syndrome follows a distinctive developmental course, with the achievement of apparently normal early milestones followed by developmental regression, deceleration of head growth, the onset of stereotypic hand movements and gait abnormalities.
The association between Rett syndrome and mutations in the methyl-CpG binding protein 2 (MECP2) gene was first identified in 1999 [2] . To date, more than 200 different pathogenic MECP2 mutations have been identified and there appears to be considerable variation in phenotype. Some mutations (p.R270X and p.R255X) are associated with a severe clinical presentation and some (p.R294X and p.R133C) with a milder phenotype [3] [4] [5] [6] [7] [8] .
Children with various neurodevelopmental disabilities have been shown to have sleep problems. Females
